In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals is now the sole owner of a drug in its pipeline. Shares in biotech company Recursion Pharmaceuticals (NASDAQ: RXRX) surged by more than 12% by 11 a.m. ET today. The move is ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Debt Management: Recursion Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.1. What Are Analyst Ratings?

Payara and Azul have formed a strategic partnership to deliver 'codeless migrations.' Our columnist believes the deal ...

Recursion Pharmaceuticals grew its share prices for a fourth straight day on Monday, adding 9.59 percent to close at $6.40 ...

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia Provided by GlobeNewswire Jul 8, 2025, 12:00:00 PM ...

Recursion Pharmaceuticals (RXRX) shares soared 5.8% in the last trading session to close at $5.84. The move was backed by solid volume with far more shares changing hands than in a normal session.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of These 10 Stocks Are Making Big Moves. Recursion Pharmaceuticals bounced back by 8.72 percent on Tuesday to close at $5.36 apiece following news ...

Recursion Pharma has agreed to merge with rival AI-powered drug discovery firm Exscientia in an all-stock deal valued at $688 million ...

A PriorityQueue is a list that always keeps its items sorted based on some rule, like smallest to largest. So, when you take an item out, you always get the one with the highest (or lowest) priority.